BioCryst Pharmaceuticals, Inc. (BCRX)
NASDAQ: BCRX · Real-Time Price · USD
7.79
-0.01 (-0.13%)
Jan 2, 2026, 10:56 AM EST - Market open
BioCryst Pharmaceuticals Employees
BioCryst Pharmaceuticals had 580 employees as of December 31, 2024. The number of employees increased by 44 or 8.21% compared to the previous year.
Employees
580
Change (1Y)
44
Growth (1Y)
8.21%
Revenue / Employee
$1,034,166
Profits / Employee
-$15,136
Market Cap
1.64B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 580 | 44 | 8.21% |
| Dec 31, 2023 | 536 | 5 | 0.94% |
| Dec 31, 2022 | 531 | 173 | 48.32% |
| Dec 31, 2021 | 358 | 112 | 45.53% |
| Dec 31, 2020 | 246 | 106 | 75.71% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
BCRX News
- 21 days ago - FDA expands approval of BioCryst's rare disease drug for use in young children - Reuters
- 21 days ago - BioCryst Announces FDA Approval of ORLADEYO® (berotralstat) Oral Pellets, First and Only Oral Prophylactic Treatment for Patients with HAE Aged 2 to - GlobeNewsWire
- 4 weeks ago - BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 weeks ago - BioCryst Receives Early Termination of HSR Waiting Period for Astria Acquisition - GlobeNewsWire
- 5 weeks ago - BioCryst Pharmaceuticals, Inc. (BCRX) Presents at Jefferies London Healthcare Conference 2025 Transcript - Seeking Alpha
- 2 months ago - BioCryst Presents New Data at ACAAI Highlighting Burden of HAE on Pediatric Patients and Caregivers and Sustained Reduction of Attacks in Children Treated with One Year of ORLADEYO® (berotralstat) - GlobeNewsWire
- 2 months ago - BioCryst to Present at Upcoming Investor Conference - GlobeNewsWire
- 2 months ago - BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2025 Earnings Call Transcript - Seeking Alpha